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Introduction
In the early 1990s, I contributed to the development of
two intimately linked hypotheses concerning breast
cancer etiology in humans. The first postulated that the
intrauterine environment may affect breast cancer risk in
the offspring in ways over and beyond those attributed to
major breast cancer genes [1]. In the second hypothesis,
the argument was made that the number of mammary
gland cells, particularly of those among them that are sus-
ceptible to transformation, is an important determinant of
breast cancer risk [2]. In other words, intrauterine and
early life events and conditions could affect the number of
mammary gland cells at risk for transformation and, ulti-
mately, breast cancer risk.
Neither of these hypotheses was developed in a vacuum.
The earlier work of several authors was instrumental, and
indeed critical. The striking protective effect on breast
cancer risk of an early first full-term pregnancy led Cole
and MacMahon to hypothesize that breast cancer risk is
established, in part, early in life [3]. Loeb, as well as other
investigators, argued that early phenomena, perhaps
affecting mutator genes or other factors controlling
genetic stability, are crucial in the process of carcinogenesis
[4]. Moolgavkar et al. postulated that the magnitude of
breast cancer risk depends on the transition rates of
normal susceptible cells to intermediate cells and then to
transformed cells [5]. Several authors in the late 1980s
suggested that energy intake during early life may affect
the number of mammary cells, mammary gland mass and,
through them, breast cancer risk [6].
Intrauterine environment and breast cancer
risk
The hypothesis that breast cancer may have intrauterine
component causes is based on a number of generally
accepted assumptions. Mammary gland cells in utero are
not terminally differentiated. Factors that increase the risk
of cancer during adult life, as do exogenous and endoge-
nous estrogens for breast cancer, may have similar effects
when they act in utero. Estrogens and other hormones
with growth enhancing properties are abundant during
pregnancy, and adult life exposures do not fully explain the
substantial variability of breast cancer occurrence
between and within populations.
Simple as it may sound, this hypothesis is very difficult to
directly evaluate. The scientific team in Sweden lead by
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Adami and Ekbom was the first that attempted to evaluate
this hypothesis using presumed positive or inverse corre-
lates of pregnancy estrogens, including birth weight and
pregnancy toxemia [7]. Pregnancy estrogens have in fact
been reported as positively associated with birth weight
[8] and inversely associated with pregnancy toxemia [9].
Several authors have subsequently carried out research
along these lines. The results up to 1999 have been
reviewed by Potischman and Troisi, who concluded that
the collective evidence is consistent with the hypothesis
that prenatal exposures, notably pregnancy estrogens, are
associated with adult life breast cancer risk [10]. More
consistent was the evidence concerning the positive asso-
ciation between birth weight and breast cancer risk in the
offspring. Vatten et al. have since reported a positive asso-
ciation from Norway [11].
It should be noted that a link between perinatal factors
and breast cancer risk in the offspring does not necessar-
ily or exclusively incriminate pregnancy estrogens, despite
the role of the latter as an important determinant of several
of these factors, including birth weight. In addition to preg-
nancy estrogens [8], insulin-like growth factor 1 has been
positively associated with birth weight [12] and there is
also evidence that alpha fetoprotein may play a role [13].
Nevertheless, among all factors that are associated with
birth weight and other perinatal events and conditions
linked to breast cancer risk in the offspring, the inherently
mammotropic pregnancy estrogens are the most likely
candidates, although by no means the only ones [14].
Indeed, a cohort study comparing women exposed in
utero to diethylstilbestrol with unexposed women reported
a greater than twofold increase in breast cancer risk [15].
This is an ongoing study of a unique cohort, and the
women involved have not yet reached the age of high
breast cancer incidence. If the results of further followup
are in line with those recently reported [15], it will be diffi-
cult to argue against the hypothesis that high in utero
estrogenic stimulation increases breast cancer risk in the
offspring.
Mammary gland mass and breast cancer risk
With respect to mammary gland mass, as distinct from
breast size, the empirical evidence linking it to breast
cancer risk is very strong. Mammographic density is a
powerful predictor of breast cancer risk and this density is
strongly associated with mammary gland mass, although
the stromal component is also likely to play an important
role [16–19]. Small-breasted women who were motivated
to have augmentation mammoplasty, and whose mammary
gland mass had to be small, were found to have reduced
breast cancer risk [20,21], although no reduction was
evident in a small cohort study that included eight breast
cancer cases [22]. Moreover, women who had undergone
surgical reduction of their breasts subsequently had
reduced breast cancer risk [23–26].
Mammary gland mass, which reflects the total number of
mammary cells and can be correlated with mammary cells
at risk for transformation, can also explain several of the
descriptive aspects of breast cancer epidemiology. One
example is breast cancer risk being higher among Cau-
casian women than among Asian women and being posi-
tively associated with adult height [2,23]. Large breast
size mostly reflects adipose tissue but, among thin
women, breast size may be a better indicator of mammary
gland mass and has been positively associated with
breast cancer risk [27,28].
The number of mammary gland cells at risk for transforma-
tion, and thus breast cancer risk, is reduced through the
process of terminal differentiation that takes place mostly
after the occurrence of the first full-term pregnancy and, to
some extent, after the occurrence of subsequent pregnan-
cies and lactation [23,29,30]. Moreover, cells at risk or at
intermediate stages of transformation may be more or less
responsive to the growth enhancing influences of estro-
gens and other mammotropic hormones, depending on
the density of the respective receptors in the nonmalig-
nant tissue. In this context, it may be of relevance that
expression of estrogen receptors α has been found to be
less common among Japanese women than among Cau-
casian women [31].
Conclusion
We have tried to integrate the existing information on
breast cancer epidemiology and apparent pathogenesis
into an etiological model that incorporates the two pre-
sented hypotheses and the data that support them [23].
The model has four components. First, the likelihood of
breast cancer occurrence depends on the number of cells
at risk and, second, the number of target cells is partially
determined early in life, probably even in utero. The third
component is that, while a pregnancy stimulates the repli-
cation of already initiated cells, it conveys long-term pro-
tection through structural changes, including terminal
cellular differentiation. Finally, in adult life, mammotropic
hormones, in conjunction with their receptors, affect the
likelihood of retention of spontaneous somatic mutations
and the rate of expansion of initiated clones.
This composite, yet simple, model accommodates most,
if not all, epidemiological aspects of breast cancer
occurrence and natural history. These include the
secular increase of breast cancer incidence during the
early part of last century, the higher risk for this disease
among higher socioeconomic class women in most
countries of the world, as well as the gradual increase of
breast cancer incidence among Asian migrants to
Western countries. All these patterns reflect concomi-
tant changes in birth size, adult birth height and breast
cancer risk. The model also accommodates the effective-
ness of prophylactic mastectomy among women at very44
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high risk on the basis of reduction of mammary gland
mass [23,32].
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